RxDoctor Payments Data

Patricia Schierenbeck

Family · Staten Island, NYNPI 1093099228

Payments from drug & device makers

$358in general payments, 2019–2025

Across 19 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • GSK$93
  • Corcept Therapeutics$48
  • Boehringer Ingelheim$24
  • Abbott$24
  • AbbVie$21
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 50th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$82,327
Medicare patients
277
Services billed
1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$133,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$65,591
OzempicSemaglutide52$49,565
JanuviaSitagliptin Phosphate42$29,300
TrulicityDulaglutide25$25,018
EliquisApixaban25$21,958
VraylarCariprazine Hcl12$16,711
LinzessLinaclotide31$16,337
FarxigaDapagliflozin Propanediol12$11,259
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$10,200
Combivent RespimatIpratropium/Albuterol Sulfate11$8,870
Breo ElliptaFluticasone/Vilanterol12$8,605
SymbicortBudesonide/Formoterol Fumarate15$3,249
SynthroidLevothyroxine Sodium41$3,148
Albuterol Sulfate HfaAlbuterol Sulfate86$2,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$93$74,196100 claims
Novo NordiskOzempic$116$49,56552 claims
AbbVieVraylar, Linzess, Synthroid$21$36,19784 claims
Boehringer IngelheimCombivent Respimat$24$8,87011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,883 family providers in New York.

Other family in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →